Results 131 to 140 of about 10,523 (190)

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL.   +11 more
europepmc   +1 more source

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Bisceglia I, Iovine M, Barbato M, Arianna R, Canale ML, Paccone A, Inno A, Scherillo M, Oliva S, Cadeddu Dessalvi C, Mauriello A, Maurea C, Fonderico C, Maratea AC, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. [PDF]

Arterioscler Thromb Vasc Biol
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, Trompet S, Bhatt DL, Bittner VA, Diaz R, Fazio S, Stevanovic I, Goodman SG, Harrington RA, White HD, Steg PG, Schwartz GG, Cobbaert CM.   +17 more
europepmc   +1 more source

Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial. [PDF]

BMC Neurol
Liu J, Li Y, Tian W, Cao H, Li X, Cheng L, Ji X, Liu J.   +7 more
europepmc   +1 more source

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Egypt Heart J
Ahmed AAS, Alkheder A, Ali MA, Abdelraouf MR, Ashour TA, Mohamed Salamah H, Mahmoud A, Hakim D.   +7 more
europepmc   +1 more source

A rare case of alirocumab (PCSK9 inhibitor)-associated acute interstitial nephritis. [PDF]

Clin Nephrol Case Stud
Habib N, Yuan C, Lightle A, Monrroy M, Mehta S.   +4 more
europepmc   +1 more source

Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events. [PDF]

Ther Clin Risk Manag
Sidelnikov E, Kalich BA, Miglins ML, Multani JK, Tuly R, Hawkins K, Baber U.   +6 more
europepmc   +1 more source

Optimizing PCSK9 Inhibitor Integration for Cardiovascular Disease Management in Pakistan. [PDF]

Clin Med Insights Cardiol
Saleem MS, Samad S, Ahmed SS, Mehmood N.
europepmc   +1 more source

Author Correction: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. [PDF]

NPJ Aging
Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, Nakano T, Shimada A, Noda M.   +8 more
europepmc   +1 more source

Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023. [PDF]

Front Cardiovasc Med
Lai P, Xu S, Liu Z, Ling J, Tian K, Yan J, Chen D, Zhong Y, Xue J.   +8 more
europepmc   +1 more source